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Abstract
Background: Potentially Inappropriate Medication (PIM) use has been studied in a variety of older adult
populations across the world. We sought to examine the prevalence and correlates of PIM use in older drivers.
Methods: We applied the American Geriatrics Society 2015 Beers Criteria to baseline data collected from the
“brown-bag” review of medications for participants of the Longitudinal Research on Aging Drivers (LongROAD)
study to examine the prevalence and correlates of PIM use in a geographically diverse, community-dwelling sample
of older drivers (n = 2949). Proportions of participants who used one or more PIMs according to the American
Geriatrics Society 2015 Beers Criteria, and estimated odds ratios (ORs) and 95% confidence intervals (CIs) of PIM use
associated with participant characteristics were calculated.
Results: Overall, 18.5% of the older drivers studied used one or more PIM. The most commonly used therapeutic
category of PIM was benzodiazepines (accounting for 16.6% of the total PIMs identified), followed by
nonbenzodiazepine hypnotics (15.2%), antidepressants (15.2%), and first-generation antihistamines (10.5%).
Compared to older drivers on four or fewer medications, the adjusted ORs of PIM use were 2.43 (95% CI 1.68–3.51)
for those on 5–7 medications, 4.19 (95% CI 2.95–5.93) for those on 8–11 medications, and 8.01 (95% CI 5.71–11.23)
for those on ≥12 medications. Older drivers who were female, white, or living in urban areas were at significantly
heightened risk of PIM use.
Conclusion: About one in five older drivers uses PIMs. Commonly used PIMs are medications known to impair
driving ability and increase crash risk. Implementation of evidence-based interventions to reduce PIM use in older
drivers may confer both health and safety benefits.
Trial registration: Not applicable.
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Background
The Beers Criteria lists potentially inappropriate medica-
tions (PIMs) that should generally be avoided in older
adults because they are ineffective or their risk of
adverse effects outweighs the benefit. First developed in
1991 [1], the Beers Criteria has since been revised five
times, with the latest version published by the American
Geriatrics Society (AGS) in 2019 [2]. Development of
the Beers Criteria was based on systematic review of
research evidence and expert panel consensus reached
through modified Delphi methods, which involved a
two-round survey of select experts in geriatrics and
pharmacotherapy on various medications and their
adverse effects [2]. In addition to the list of PIMs that
should generally be avoided in older adults, the Beers
Criteria includes medications that should be avoided in
older adults with specific diseases or syndromes (e.g.,
non-steroidal anti-inflammatory drugs [NSAIDs] and
COX-2 inhibitors for older adults diagnosed with heart
failure because of the risk of fluid retention and
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exacerbation of cardiac symptoms), and medications that
should be used with caution in specific populations (e.g.,
clopidogrel for adults aged 75 years and older because of
the heightened risk of bleeding). The Beers Criteria has
also identified drugs for which the dose should be ad-
justed based on the patient’s renal function or concur-
rent use of other drugs that may result in drug-drug
interactions [2].
Although the Beers Criteria was originally designed as
a clinical tool for reducing PIM use and related harms in
nursing home residents, it has evolved into an integral
part of healthcare policy and best practice in geriatrics
[3], and is applicable to all older adults except those in
palliative and end-of-life care. Adherence to the Beers
Criteria is also used as a measure of healthcare quality
by the National Committee for Quality Assurance [3]. In
the past two decades, numerous studies have used the
Beers Criteria to examine the prevalence of PIM use and
associated health consequences in different population
groups, such as residents of long-term care facilities, am-
bulatory care patients, patients filling prescriptions at
pharmacies, and community-dwelling older adults [3, 4].
Because the scope of the Beers Criteria has expanded
over the years to cover more medications and clinical
scenarios, studies based on different versions of the
Beers Criteria are not directly comparable. The re-
ported prevalence of PIM use in older adults varies
with study settings, ranging from about 20% in
community-dwelling older adults [5, 6] to about 50%
in older adults presenting to primary care clinics [7],
and over 70% in older adult inpatients [8, 9]. Among
the most commonly used PIMs are NSAIDs, antihista-
mines, and benzodiazepines [8, 10]. Older adults in
poor health who are taking a large number of medica-
tions are at increased risk of PIM use [6, 10]. Use of
PIMs in older adults has been recognized as an im-
portant cause of adverse drug reactions [11, 12] and
excess healthcare costs [13], and has been linked to in-
creased risk of hospitalization and death [4].
Medication use in older drivers is common [14]. Ac-
cording to the 2011 National Health and Aging Trends
Study, over 90% of older drivers were taking at least one
prescription medication and two-thirds were taking two
or more medications [15]. As aging of the US population
continues, the effects of medications on driving safety
are of increasing concern. Although a variety of medica-
tions—such as prescription opioids, antihistamines, anti-
depressants, benzodiazepines and sleep medications—
have been linked to increased crash risk [16–18], little is
known about the magnitude of PIMs in the driver popu-
lation and the implication of PIMs for driving safety.
The purpose of the present study is to examine the
prevalence and correlates of PIM use in a large sample
of community-dwelling older drivers.
Methods
Data for this study came from the Longitudinal Research
on Aging Drivers (LongROAD) project − a multisite
prospective cohort study. The LongROAD project was
designed to address major questions pertaining to the
safety and wellbeing of older drivers, such as the effects
of medical conditions and medications on driving behav-
ior and safety, and the determinants and health conse-
quences of driving cessation during the process of aging.
Between July 2015 and March 2017, the research team
recruited a total of 2990 active drivers aged 65–79 years
from primary care clinics or healthcare systems in five
study sites (Ann Arbor, MI; Baltimore, MD; Coopers-
town, NY; Denver, CO; and San Diego, CA). The local
Institutional Review Board at each site approved this
study. Following informed consent, each driver was
assessed at baseline with standardized research protocols
and instruments, including a baseline questionnaire,
medical record abstraction, functional tests (e.g., grip
strength) and a “brown-bag” review of medications. For
the latter, research staff instructed the study participants
to bring all current medications (both prescribed and
over-the-counter) and supplements with them for
review; detailed information was collected about each
medication used. The study design and research protocol
for the LongROAD project is described in detail else-
where [19].
Medication data collected at baseline were coded
according to the pharmacologic/therapeutic classifica-
tion system established by the American Society of
Health-Systems Pharmacists in the American Hospital
Formulary Service (AHFS) Clinical Drug Information
[20]. The AHFS classification system groups medications
with similar pharmacologic, therapeutic, and chemical
characteristics in a four-tier hierarchy, with 31 possible
categories in the first tier, 189 in the second tier, 269 in
the third tier, and 105 in the fourth tier [20]. Baseline
medication data were available for 2949 (98.6%) of the
2990 study participants. A total of 24,690 medications
were recorded from the “brown-bag” review at baseline;
of them, 22,856 (92.6%) were coded successfully with the
AHFS classification system. Non-coded medications
included food-like items (e.g., flaxseed oil, protein),
homeopathic products (e.g., herbs and spices), and other
supplements (e.g., witch-hazel, glucosamine) [21].
The 2015 AGS Beers Criteria for PIM use in older
adults (the latest version at the time of this study) was
applied to the AHFS-coded medication data to identify
PIMs in the study sample [22]. Where necessary, diagno-
sis data from the study participant’s medical records and
self-reported health conditions were reviewed to confirm
that the criteria specified in the 2015 AGS Beers Criteria
were met. Included in the analysis were PIMs that
should generally be avoided, exclusive of proton-pump
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inhibitors. The 2015 AGS Beers Criteria recommends
avoiding long-term (> 8 weeks) use of proton-pump
inhibitors except for high-risk patients (e.g., those on
oral corticosteroids or chronic NSAIDs). Proton-pump
inhibitors, which were used by 21.7% (638 participants)
in the study sample, were excluded from the analysis be-
cause data from the “brown-bag” review were insuffi-
cient to accurately assess the duration of the scheduled
use of the medication and users’ risk status. Also
excluded from the analysis were: 1) medications for
which an accurate assessment of inappropriateness could
not be made due to a lack of clinical data on comorbid
conditions, indication for use, toxicity, and/or route of
administration; 2) medications to avoid for older adults
with specific diseases or syndromes; 3) medications to
be used with caution due to drug-drug interactions; and
4) anti-infective medications that should be avoided or
have their dosage adjusted according to renal function
levels [22].
Prevalence of PIM use was calculated according to
demographic and health characteristics. For frailty, a
3-category variable was created based on the Fried
frailty phenotype: 0, not frail; 1–2, pre-frail; and 3–5,
frail [23]. Urbanicity of participant residence was clas-
sified using rural-urban commuting area (RUCA)
codes derived from ZIP codes in home addresses:
urban (RUCA codes 1 and 1.1 [metropolitan core]);
suburban (RUCA codes 2, 2.1 and 3 [metropolitan
area non-core]); and rural (RUCA codes 4–10 [micro-
politan, small towns or rural]) [24].
Differences in the prevalence of PIM use across vari-
ables were assessed with chi-square tests. All the covari-
ates of interest and statistical significance at p = 0.05
level in the bivariate analysis, except the variable indicat-
ing study site, were included in the final multivariable
logistic regression model to obtain the adjusted odds ra-
tios (ORs) and their corresponding 95% confidence in-
tervals (CIs) of PIM use.
Results
Overall, 545 out of the 2949 study participants with medi-
cation data available used at least one PIM, yielding a point
prevalence of 18.5%. The prevalence of PIM use varied sig-
nificantly with age, sex, race/ethnicity, and marital status
(Table 1). Specifically, higher prevalence of PIM use was
found in drivers who were female, white, or not currently
married (Table 1). The most pronounced difference in the
prevalence of PIM use with regard to demographic charac-
teristics was between sexes, with female drivers being nearly
twice as likely as male drivers to use PIMs (23.8% vs. 12.4%,
p < 0.0001). PIM use was not significantly associated with
education or household income levels.
When measured by frailty score, 41.2% of the study
participants was classified as not frail, 55.9% as pre-frail,
and 2.9% as frail. The prevalence of PIM use was 17.8%
for those in the “not frail” group, 18.5% in the “pre-fail”
group and 24.7% in the “frail” group (p = 0.286; Table 1).
The prevalence of PIM use increased progressively
with the total number of medications used. Use of PIMs
was highest among older drivers taking 12 or more med-
ications; over one-third (34.3%) of this group used PIMs,
compared with 21.4% of those on 8–11 medications,
13.4% of those on 5–7 medications and 6.0% of those on
four or fewer medications (p < 0.001; Fig. 1).
The prevalence of PIM use varied with study sites,
ranging from 14.8% for drivers recruited in Coopers-
town, NY to 21.9% for drivers recruited in San Diego,
CA (Table 1). Almost three-quarters (72.8%) of the
drivers studied were living in urban areas, 14.0% in sub-
urban areas, and 13.2% in rural areas. The prevalence of
PIM use among older drivers in urban areas was 20.1%,
significantly higher than in suburban areas (13.6%) and
rural areas (14.7%) (p = 0.001; Fig. 2).
Use of multiple PIMs was fairly common. Of the 545
PIM users, 95 (17.4%) used two or more PIMs. The most
frequently used therapeutic category of PIM was short-
and intermediate acting benzodiazepines such as
alprazolam, lorazepam and temazepam, accounting for
16.6% of the total PIMs identified. Other frequently used
PIMs were nonbenzodiazepine hypnotics (e.g., eszopi-
clone, zolpidem and zalepon; 16.4%), antidepressants
(e.g., amitriptyline and clomipramine; 15.2%), first-
generation antihistamines (e.g., chlorpheniramine and
diphenhydramine; 10.5%), estrogens (oral and topical;
10.4%), skeletal muscle relaxants (e.g., carisoprodol and
metaxalone; 8.6%), and NSAIDs (e.g., ibuprofen and na-
proxen; 7.4%) (Table 2). Together, these seven thera-
peutic categories accounted for 85.1% of the total PIMs.
Multivariable logistic regression modeling revealed
that the total number of medications used was most
strongly associated with PIM use; relative to older
drivers on four or fewer medications, the adjusted
ORs of PIM use were 2.43 (95% CI 1.68–3.51) for
those on 5–7 medications, 4.19 (95% CI 2.95–5.93)
for those on 8–11 medications, and 8.01 (95% CI
5.71–11.23) for those on ≥12 medications. When the
total number of medications used was treated as a
continuous variable in the multivariable logistic
regression model, the odds of PIM use increased 13%
(adjusted OR 1.13; 95% CI 1.11–1.15) with each unit
increase in the total number of medications. Other
variables significantly associated with PIM use were
sex, race/ethnicity, and urbanicity. Specifically, older
drivers who were female, white, or living in urban
areas were at significantly increased risk of PIM use
(Table 3). There were no significant interaction effects
on PIM use between these variables. Because older
drivers representing rural areas in the study sample
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Table 1 Prevalence of Potentially Inappropriate Medication (PIM) use in older drivers by demographic characteristics, the
Longitudinal Research on Aging Drivers (LongROAD) study
Characteristic No. of drivers No. of drivers using one or
more PIMa
Prevalence (%) p-value
Overall 2949 545 18.5
Age at baseline (years) 0.244
65–69 1222 225 18.4
70–74 1027 177 17.2
75–79 700 143 20.4
Sex 0.000
Male 1382 172 12.4
Female 1567 373 23.8
Race/Ethnicity 0.004
White, non-Hispanic 2526 491 19.4
Black, non-Hispanic 207 24 11.6
Hispanic 80 15 18.8
Asian 65 5 7.7
Other 71 10 14.1
Marital Status 0.003
Married 1850 307 16.6
Divorced 439 105 23.9
Widowed 371 81 21.8
Never married 128 23 18.0
Other 161 29 18.0
Education 0.248
Less than high school 70 13 18.6
High school 265 43 16.2
Some college/Associate’s degree 715 152 21.3
Bachelor’s degree 691 126 18.2
Advanced degree 1208 211 17.5
Household Income in the previous year 0.332
< $20,000 131 31 23.7
$20,000–$49,999 633 118 18.6
$50,000–$79,999 710 133 18.7
$80,000–$99,999 427 67 15.7
≥ 100,000 942 174 18.5
Frailty score 0.286
Not frail 1205 215 17.8
Pre-frail 1636 302 18.5
Frail 85 21 24.7
Study Site 0.005
Ann Arbor, MI 595 102 17.1
Baltimore, MD 583 100 17.2
Cooperstown, NY 595 88 14.8
Denver, CO 577 124 21.5
San Diego, CA 599 131 21.9
aIncludes 450 drivers using one PIM, 76 using two PIMs, 15 using three PIMs, 3 using four PIMs, and 1 using five PIMs
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came primarily from Cooperstown, NY, study site was
not included in the multivariate analysis.
Discussion
The prevalence of PIM use found in this study, 18.5%, is
lower than reported in studies conducted in clinical settings
involving different patient groups [7, 8] but is generally
comparable to findings from studies in community-
dwelling older adults and non-institutionalized Medicare
beneficiaries [13, 25]. The relatively low use of PIMs
reported in this study is likely due to three factors. First, the
study sample was comprised of older drivers who were
more active and healthier than the general older adult
population [19]. For example, less than 3% of the drivers
included in this study were classified as frail according to
the Fried frailty phenotype, compared with about 11% in
the community dwelling older adult population [26].
Second, the prevalence of PIM use reported in this study
was based on all participants with medication review data,
including those who were found to be not taking any medi-
cations (3.3% of the study sample). Previous studies of PIMs
were mostly restricted to older adults who were taking one
or more medications. Finally, the estimated prevalence of
PIM use in this study is likely conservative because we
Fig. 1 Prevalence of Potentially Inappropriate Medication (PIM) use by urbanicity in older adult drivers, the Longitudinal Research on Aging
Drivers (LongROAD) study
Fig. 2 Prevalence of Potentially Inappropriate Medication (PIM) use by total number of medications used in older adult drivers, the Longitudinal
Research on Aging Drivers (LongROAD) study
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excluded proton-pump inhibitors and a few other medica-
tions on the list of PIMs due to insufficient clinical data
necessary for applying the AGS 2015 Beers Criteria to these
medications, such as duration, dosage, and user’s risk sta-
tus. Several studies have reported that proton-pump
inhibitors are one of the most commonly used PIMs in
older adults [9, 25]. Our data indicate that 21.7% of the
older drivers included in this study were taking proton-
pump inhibitors, although it is unclear whether this thera-
peutic category of PIM was used inappropriately according
to the AGS 2015 Beers Criteria.
Previous studies have identified several demographic
and clinical characteristics associated with PIM use,
including age, sex, race, health status, and total number
of medications used. Findings from our study are gener-
ally consistent with the existent research literature.
Because of the favorable health status of study partici-
pants, associations of age and health status (as measured
by frailty status) with PIM use did not reach statistical
significance. As the participants grow older and more
frail, we expect that the associations of advancing age
and declining health status with PIM use may manifest
in the follow-up data. Although other researchers have
reported a higher prevalence of PIM use in older women
than in older men [9, 25, 27], our study reveals that the
excess prevalence of PIMs in women was due in a large
part to use of estrogens. Furthermore, data from the
multisite LongROAD project allowed us to identify the
geographical gradient in PIM use. Specifically, we found
that older drivers living in urban areas were about 60%
more likely to use PIMs than those living in rural and
suburban areas, with adjustment for demographic
characteristics, frailty status, and total number of medi-
cations used. Prior studies of urbanicity and PIM use by
older adults have produced inconsistent results. Inappro-
priate medication prescribing has sometimes been
reported as similar in urban and rural locations [6, 28]
or as more common for urban patients [29] or rural
patients [30]. An analysis of Veterans Administration
data on elder veterans found that urban-rural differences
in prescribing quality varied by region of the country,
with inappropriate prescribing associated with rural
locations in the South and Northeast but urban locations
in the West [31]. Previous research suggests that older
adults in the West, Midwest, and South regions are at
greater risk of using PIMs than in the Northeast [32].
Our finding of urbanicity as a risk marker, if confirmed
by other researchers, may help enhance intervention
programs by better targeting populations at high-risk for
PIM use to improve health outcomes in older adults.
The PIMs included in the Beers Criteria should gener-
ally be avoided in older adults because they are thera-
peutically ineffective or pose an exceptionally high risk
of adverse effects, such as delirium, internal bleeding,
Table 2 Sex-specific frequencies of potentially inappropriate
medications by therapeutic category in older drivers, the







Benzodiazepines 27 (14.0) 83 (17.6) 110 (16.6)
Nonbenzodiazepine Hypnotics 45 (23.3) 64 (13.6) 109 (16.4)
Antidepressants 24 (12.4) 77 (16.3) 101 (15.2)
First-Generation Antihistamines 22 (11.4) 48 (10.2) 70 (10.5)
Estrogens (Oral and Patch) 0 (0.0) 69 (14.7) 69 (10.4)
Skeletal Muscle Relaxants 15 (7.8) 42 (8.9) 57 (8.6)
NSAIDs (Oral) 22 (11.4) 27 (5.7) 49 (7.4)
Antispasmodics 9 (4.6) 24 (5.1) 33 (5.0)
Antipsychotics 4 (2.1) 12 (2.6) 16 (2.4)
Sulfonylureas (Long duration) 8 (4.1) 3 (0.6) 11 (1.6)
Otherb 17 (8.8) 22 (4.7) 39 (5.9)
Total 193 (100.0) 471 (100.0) 664 (100.0)
aIncludes 450 drivers using one PIM, 76 using two PIMs, 15 using three PIMs, 3
using four PIMs, and 1 using five PIMs
bIncludes 9 drivers (0 M, 9 F) on barbiturates, 6 (5 M, 1 F) on dronedarone, 6 (5
M, 1 F) on insulin (sliding scale), 4 (0 M, 4 F) on nitrofuratonin, 3 on androgens
(3 M, 0 F), 3 (1 M, 2 F) on metoclopramide, 3 (2 M, 1 F) on desmopressin, 2 (0 M,
2 F) on peripheral alpha-1 blockers, 2 (1 M, 1 F) on mineral oil (oral), and 1
(0 M, 1 F) on antiparkinsonian agents
Table 3 Adjusted Odds Ratios (ORs) and 95% Confidence
Intervals (CIs) of Potentially Inappropriate Medication (PIM) use
in older drivers by risk markers, the Longitudinal Research on
Aging Drivers (LongROAD) study





White, non-Hispanic 1.00 reference













OR Odds Ratio; 95% CI = 95% Confidence Interval
aAdjusted for age, marital status and frailty phenotype in addition to variables
in the table
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and injury resulting from falls. For some PIMs, safer
alternative medications or non-pharmaceutical therapies
are available. Previous studies examining the conse-
quences of PIM use were focused on adverse health out-
comes, such as drug reactions, complications, morbidity
and mortality [4, 33]. Our study provides, for the first
time, detailed data on PIMs used by older drivers. Most
of the commonly used PIMs identified in this study,
such as benzodiazepines, nonbenzodiazepine hypnotics,
antidepressants, and first-generation antihistamines, are
medications known to impair driving performance and
increase crash risk [17, 18, 34, 35]. For example, meta-
analyses have shown that use of benzodiazepines is asso-
ciated with 60–80% increased risk of crash involvement
and 40% increased risk of crash culpability and that
older adults are particularly susceptible to the deleteri-
ous effect of antidepressants on driving safety [18, 34].
Our study indicates that about 11% of older drivers use
benzodiazepines, nonbenzodiazepine hypnotics, antide-
pressants, or first-generation antihistamines – PIMs that
can impair driving ability and increase crash risk.
There are several limitations with this study. First, the
Beers Criteria is a clinical tool designed to identify and
evaluate potentially inappropriate medications that
should generally be avoided in older adults. These quali-
fiers are necessary because there could be particular
clinical circumstances under which use of a PIM might
be justified. Second, the prevalence of PIMs reported in
this study is likely a conservative estimate because our
analysis was restricted to PIMs that should generally be
avoided in older adults and because our analysis
excluded proton-pump inhibitors due to insufficient data
about the duration of usage and the user’s risk status.
Other studies reporting much higher prevalence of PIM
use may have included additional medications identified
in the AGS 2015 Beers Criteria for their risks of drug-
disease and drug-drug interactions, such as opioids for
older adults with a history of falls or fractures [36, 37].
Finally, this study relied on an analysis of medication
review data collected as part of the baseline assess-
ment in the LongROAD project and therefore is cross-
sectional in nature. Future research should incorporate
prospectively collected follow-up data to understand the
trajectory of PIM use during the process of aging and the
relationships between PIM use and driving outcomes,
such as safety behavior and crash risk.
Conclusion
In summary, this study provides valuable empirical evi-
dence for understanding the magnitude of PIM use in
older drivers and sheds light on the factors associated
with PIM use and specific medications involved. Our
conservative estimate indicates that nearly a fifth of
older drivers use one or more PIMs. The odds of PIM
use increases with the total number of medications being
taken and is particularly high among white, female older
drivers living in urban areas. The PIMs most commonly
used by older drivers are benzodiazepines, nonbenzodia-
zepine hypnotics, antidepressants, and first-generation
antihistamines, all of which have been linked to driving
impairment and increased crash risk. Implementation of
evidence-based interventions, such as computer-based
alerts and prescription rule restrictions [38], may reduce
PIM use and improve health outcomes and driving
safety in older adults.
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